0000950170-24-078772.txt : 20240628 0000950170-24-078772.hdr.sgml : 20240628 20240628073005 ACCESSION NUMBER: 0000950170-24-078772 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Politi Jason CENTRAL INDEX KEY: 0002026944 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 241081367 MAIL ADDRESS: STREET 1: C/O VERVE THERAPEUTICS, INC. STREET 2: 201 BROOKLINE AVENUE, SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 3 1 ownership.xml 3 X0206 3 2024-06-26 0 0001840574 Verve Therapeutics, Inc. VERV 0002026944 Politi Jason C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 false true false false Chief Technical Ops. Off. Common Stock 6266 D Stock Option (right to buy) 8.24 2031-02-18 Common Stock 118796 D Stock Option (right to buy) 30.94 2032-02-10 Common Stock 69000 D Stock Option (right to buy) 21.76 2033-02-13 Common Stock 53170 D Restricted Stock Units Common Stock 9945 D Stock Option (right to buy) 11.57 2033-10-15 Common Stock 25000 D Stock Option (right to buy) 12.75 2034-02-13 Common Stock 90000 D Restricted Stock Units Common Stock 22000 D The option was granted on February 19, 2021. 25% of the shares underlying the option vested on February 25, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 25, 2025. The option was granted on February 11, 2022. 25% of the shares underlying the option vested on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026. The option was granted on February 14, 2023. 25% of the shares underlying the option vested on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027. On February 14, 2023, the reporting person was granted 13,260 restricted stock units, vesting in four equal annual installments that began on April 1, 2024 and the remaining three installments vesting on April 1, 2025, April 1, 2026 and April 1, 2027. The option was granted on October 16, 2023. 25% of the shares underlying the option will vest on October 16, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until October 16, 2027. The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028. On February 14, 2024, the reporting person was granted 22,000 restricted stock units, vesting in four equal annual installments beginning on April 1, 2025 and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock. Exhibit Index 24.1 Power of Attorney /s/ Andrew Ashe, as Attorney-in-Fact for Jason Politi 2024-06-28 EX-24.POLITIPOA 2 verv-ex24_politipoa.htm EX-24.POLITIPOA EX-24.PolitiPOA

Exhibit 24.1

 

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

 

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Andrew Ashe, Allison Dorval and Yasser El-Gamal, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or stockholder of Verve Therapeutics, Inc. (the “Company”), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the “Exchange Act”);

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the “SEC”) and any stock exchange or similar authority, including, without limitation, the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(3) seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney‑in‑fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney‑in‑fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney‑in‑fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney‑in‑fact may approve in such attorney‑in‑fact’s discretion.

The undersigned hereby grants to each such attorney‑in‑fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney‑in‑fact, or such attorney‑in‑fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys‑in‑fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys‑in‑fact assume (i) any liability for the undersigned’s responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys‑in‑fact.

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26th day of June, 2024.

 

/s/ Jason Politi

Jason Politi

-2-